Cargando…

Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study

AIMS : The potential difference in the impacts of lifestyle factors (LFs) on progression from healthy to first cardiometabolic disease (FCMD), subsequently to cardiometabolic multimorbidity (CMM), and further to death is unclear. METHODS AND RESULTS : We used data from the China Kadoorie Biobank of...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Yuting, Hu, Yizhen, Yu, Canqing, Guo, Yu, Pei, Pei, Yang, Ling, Chen, Yiping, Du, Huaidong, Sun, Dianjianyi, Pang, Yuanjie, Chen, Ningyu, Clarke, Robert, Chen, Junshi, Chen, Zhengming, Li, Liming, Lv, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423468/
https://www.ncbi.nlm.nih.gov/pubmed/34333624
http://dx.doi.org/10.1093/eurheartj/ehab413
_version_ 1783749470134992896
author Han, Yuting
Hu, Yizhen
Yu, Canqing
Guo, Yu
Pei, Pei
Yang, Ling
Chen, Yiping
Du, Huaidong
Sun, Dianjianyi
Pang, Yuanjie
Chen, Ningyu
Clarke, Robert
Chen, Junshi
Chen, Zhengming
Li, Liming
Lv, Jun
author_facet Han, Yuting
Hu, Yizhen
Yu, Canqing
Guo, Yu
Pei, Pei
Yang, Ling
Chen, Yiping
Du, Huaidong
Sun, Dianjianyi
Pang, Yuanjie
Chen, Ningyu
Clarke, Robert
Chen, Junshi
Chen, Zhengming
Li, Liming
Lv, Jun
author_sort Han, Yuting
collection PubMed
description AIMS : The potential difference in the impacts of lifestyle factors (LFs) on progression from healthy to first cardiometabolic disease (FCMD), subsequently to cardiometabolic multimorbidity (CMM), and further to death is unclear. METHODS AND RESULTS : We used data from the China Kadoorie Biobank of 461 047 adults aged 30–79 free of heart disease, stroke, and diabetes at baseline. Cardiometabolic multimorbidity was defined as the coexistence of two or three CMDs, including ischaemic heart disease (IHD), stroke, and type 2 diabetes (T2D). We used multi-state model to analyse the impacts of high-risk LFs (current smoking or quitting because of illness, current excessive alcohol drinking or quitting, poor diet, physical inactivity, and unhealthy body shape) on the progression of CMD. During a median follow-up of 11.2 years, 87 687 participants developed at least one CMD, 14 164 developed CMM, and 17 541 died afterwards. Five high-risk LFs played crucial but different roles in all transitions from healthy to FCMD, to CMM, and then to death. The hazard ratios (95% confidence intervals) per one-factor increase were 1.20 (1.19, 1.21) and 1.14 (1.11, 1.16) for transitions from healthy to FCMD, and from FCMD to CMM, and 1.21 (1.19, 1.23), 1.12 (1.10, 1.15), and 1.10 (1.06, 1.15) for mortality risk from healthy, FCMD, and CMM, respectively. When we further divided FCMDs into IHD, ischaemic stroke, haemorrhagic stroke, and T2D, we found that LFs played different roles in disease-specific transitions even within the same transition stage. CONCLUSION : Assuming causality exists, our findings emphasize the significance of integrating comprehensive lifestyle interventions into both health management and CMD management.
format Online
Article
Text
id pubmed-8423468
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-84234682021-09-09 Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study Han, Yuting Hu, Yizhen Yu, Canqing Guo, Yu Pei, Pei Yang, Ling Chen, Yiping Du, Huaidong Sun, Dianjianyi Pang, Yuanjie Chen, Ningyu Clarke, Robert Chen, Junshi Chen, Zhengming Li, Liming Lv, Jun Eur Heart J Clinical Research AIMS : The potential difference in the impacts of lifestyle factors (LFs) on progression from healthy to first cardiometabolic disease (FCMD), subsequently to cardiometabolic multimorbidity (CMM), and further to death is unclear. METHODS AND RESULTS : We used data from the China Kadoorie Biobank of 461 047 adults aged 30–79 free of heart disease, stroke, and diabetes at baseline. Cardiometabolic multimorbidity was defined as the coexistence of two or three CMDs, including ischaemic heart disease (IHD), stroke, and type 2 diabetes (T2D). We used multi-state model to analyse the impacts of high-risk LFs (current smoking or quitting because of illness, current excessive alcohol drinking or quitting, poor diet, physical inactivity, and unhealthy body shape) on the progression of CMD. During a median follow-up of 11.2 years, 87 687 participants developed at least one CMD, 14 164 developed CMM, and 17 541 died afterwards. Five high-risk LFs played crucial but different roles in all transitions from healthy to FCMD, to CMM, and then to death. The hazard ratios (95% confidence intervals) per one-factor increase were 1.20 (1.19, 1.21) and 1.14 (1.11, 1.16) for transitions from healthy to FCMD, and from FCMD to CMM, and 1.21 (1.19, 1.23), 1.12 (1.10, 1.15), and 1.10 (1.06, 1.15) for mortality risk from healthy, FCMD, and CMM, respectively. When we further divided FCMDs into IHD, ischaemic stroke, haemorrhagic stroke, and T2D, we found that LFs played different roles in disease-specific transitions even within the same transition stage. CONCLUSION : Assuming causality exists, our findings emphasize the significance of integrating comprehensive lifestyle interventions into both health management and CMD management. Oxford University Press 2021-08-01 /pmc/articles/PMC8423468/ /pubmed/34333624 http://dx.doi.org/10.1093/eurheartj/ehab413 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Research
Han, Yuting
Hu, Yizhen
Yu, Canqing
Guo, Yu
Pei, Pei
Yang, Ling
Chen, Yiping
Du, Huaidong
Sun, Dianjianyi
Pang, Yuanjie
Chen, Ningyu
Clarke, Robert
Chen, Junshi
Chen, Zhengming
Li, Liming
Lv, Jun
Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study
title Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study
title_full Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study
title_fullStr Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study
title_full_unstemmed Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study
title_short Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study
title_sort lifestyle, cardiometabolic disease, and multimorbidity in a prospective chinese study
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423468/
https://www.ncbi.nlm.nih.gov/pubmed/34333624
http://dx.doi.org/10.1093/eurheartj/ehab413
work_keys_str_mv AT hanyuting lifestylecardiometabolicdiseaseandmultimorbidityinaprospectivechinesestudy
AT huyizhen lifestylecardiometabolicdiseaseandmultimorbidityinaprospectivechinesestudy
AT yucanqing lifestylecardiometabolicdiseaseandmultimorbidityinaprospectivechinesestudy
AT guoyu lifestylecardiometabolicdiseaseandmultimorbidityinaprospectivechinesestudy
AT peipei lifestylecardiometabolicdiseaseandmultimorbidityinaprospectivechinesestudy
AT yangling lifestylecardiometabolicdiseaseandmultimorbidityinaprospectivechinesestudy
AT chenyiping lifestylecardiometabolicdiseaseandmultimorbidityinaprospectivechinesestudy
AT duhuaidong lifestylecardiometabolicdiseaseandmultimorbidityinaprospectivechinesestudy
AT sundianjianyi lifestylecardiometabolicdiseaseandmultimorbidityinaprospectivechinesestudy
AT pangyuanjie lifestylecardiometabolicdiseaseandmultimorbidityinaprospectivechinesestudy
AT chenningyu lifestylecardiometabolicdiseaseandmultimorbidityinaprospectivechinesestudy
AT clarkerobert lifestylecardiometabolicdiseaseandmultimorbidityinaprospectivechinesestudy
AT chenjunshi lifestylecardiometabolicdiseaseandmultimorbidityinaprospectivechinesestudy
AT chenzhengming lifestylecardiometabolicdiseaseandmultimorbidityinaprospectivechinesestudy
AT liliming lifestylecardiometabolicdiseaseandmultimorbidityinaprospectivechinesestudy
AT lvjun lifestylecardiometabolicdiseaseandmultimorbidityinaprospectivechinesestudy
AT lifestylecardiometabolicdiseaseandmultimorbidityinaprospectivechinesestudy